Octapharma   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Lachen Switzerland (1983)
Status: No NME R&D (1983)

Organization Overview

First Clinical Trial
2002
NCT00545493
First Marketed Drug
2004
immune globulin (human) (Gamastan)
First NDA Approval
2013
blood plasma
Last Known Activity
2024

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Octapharma | Octapharma AG | Octapharma Pharmazeutika Produktionsges.m.b.H. | Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria